Kera Capital Partners’s Phathom Pharmaceuticals PHAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$196K Buy
26,830
+4
+0% +$38 0.02% 671
2026
Q2
$291K Hold
26,826
– – 0.03% 499
2026
Q1
$298K Buy
26,826
+2,571
+11% +$32.5K 0.04% 412
2025
Q4
$332K Sell
24,255
-5,804
-19% -$82.9K 0.04% 373
2025
Q3
$354K Hold
30,059
– – 0.05% 245
2025
Q2
$288K Buy
30,059
+210
+0.7% +$1.16K 0.06% 211
2025
Q1
$187K Buy
29,849
+3,000
+11% +$18.2K 0.06% 181
2024
Q4
$218K Buy
+26,849
New +$332K 0.06% 128

Other funds holding PHAT

Kera Capital Partners's PHAT Position: Q3 2026 in Review

Kera Capital Partners increased its Phathom Pharmaceuticals (PHAT) stake by 0.01% in Q3 2026, buying an estimated $38 and bringing the position to 26,830 shares worth $196K. The position accounts for 0.02% of the portfolio, ranked #671.

Kera Capital Partners first reported a position in PHAT in Q4 2024 and has held it in 8 quarters since. The position peaked at $354K in Q3 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q3 2026.

  • Kera Capital Partners held 26,830 shares of Phathom Pharmaceuticals worth $196K as of Q3 2026.
  • Kera Capital Partners bought 4 Phathom Pharmaceuticals shares in Q3 2026, an estimated $38.
  • Phathom Pharmaceuticals made up 0.02% of Kera Capital Partners's portfolio in Q3 2026, its #671 holding.
  • Kera Capital Partners first reported a position in Phathom Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
  • Kera Capital Partners's Phathom Pharmaceuticals position peaked at $354K in Q3 2025.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2026.

Based on Kera Capital Partners's 13F filing for Q3 2026, filed 13 Nov 2026.